Procoagulant properties of bare and highly PEGylated vinyl-modified silica nanoparticles.
OBJECTIVE
Undesired alterations of the blood clotting balance may follow the intravascular injection of nanotherapeutics/diagnostics. Here, we tested the procoagulant activity of synthetic amorphous silica (SAS) and organically modified silica (ORMOSIL) nanoparticles (NPs) and whether a high-density polyethylene glycol coating minimizes these effects.


METHODS
Hageman factor- and tissue factor-dependent activation of human blood/plasma coagulation, and binding to human monocytes, endothelial cells and platelets were quantified in vitro using naked and PEGylated ORMOSIL-NPs. Their effects were compared with those of SAS-NPs, present in many industrial products, and of poly(lactic-co-glycolic acid)- and small unilamellar vesicles-NPs, already approved for use in humans.


RESULTS
Both SAS-NPs and ORMOSIL-NPS presented a significant procoagulant activity. However, highly PEGylated ORMOSIL-NPs were particularly averse to the interaction with the soluble factors and cellular elements that may lead to intravascular blood coagulation.


CONCLUSIONS
Stealth, highly PEGylated ORMOSIL-NPs with a poor procoagulant activity can be used as starting blocks to design hemocompatible nanomedical-devices.
Tavano
Regina
R
Dipartimento di Scienze Biomediche Sperimentali, Università di Padova, Padova, Italy.
Segat
Daniela
D
Reddi
Elena
E
Kos
Janko
J
Rojnik
Matija
M
Kocbek
Petra
P
Iratni
Selma
S
Scheglmann
Dietrich
D
Colucci
Mario
M
Echevarria
Iria Maria Rio
IM
Selvestrel
Francesco
F
Mancin
Fabrizio
F
Papini
Emanuele
E
D003029:Coagulants; D006801:Humans; D053758:Nanoparticles; D011092:Polyethylene Glycols; D012822:Silicon Dioxide
D003029:Coagulants; D011092:Polyethylene Glycols; D012822:Silicon Dioxide